Skip to main content
SpringerLink
Log in

Update of cardiovascular drug interactions

  • Chapter
Progress in Drug Research

Part of the book series: Progress in Drug Research ((PDR,volume 29))

  • 70 Accesses

Abstract

An increasing number of clinical studies address interactions of cardiovascular drugs in terms of both their importance in the treatment of disease and their potential to cause drug-induced toxicity. Several books and reviews are devoted to extensive listings of both observed and theoretical drug interactions [1–4]. Such listings often include extrapolation of animal data, anecdotal case reports, and interactions of questionable importance. Consequently, their literal use could result in withholding therapy or overcomplicating therapeutic decisions. Some drug interactions are critical for optimum patient care, such as combined use of drugs for their additive or synergistic effects, while others, although academically interesting, have little clinical relevance. In this review, it is not our intent to provide extensive listings of cardiovascular drug interactions but to use clinical examples to illustrate pharmacological principles which may then be extrapolated to individual patients [5].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hansen, P. D.: Drug Interactions. Lea, Febiger, Philadelphia 1979.

    Google Scholar 

  2. Morselli, P. L, Garattini, S., Cohen, S. N.: Drug Interactions. Raven Press, New York 1974.

    Google Scholar 

  3. Prescott, L. F.: Pharmacokinetic drug interactions. Lancet II, 1239–1243 (1969).

    Google Scholar 

  4. Stockley, I.: Drug Interactions. Blackwell Scientific Publications, Oxford 1981.

    Google Scholar 

  5. Melmon, K. L., and Nierenberg, D. W.: Drug interactions and the prepared observer. N. Engl. J. Med. 304, 723–724 (1981) (editorial).

    Google Scholar 

  6. Sellers, E. M.: Plasma protein displacement interactions are rarely of clinical significance. Pharmacology 18, 225–227 (1979).

    Google Scholar 

  7. Bint, A. J., and Burtt, I.: Adverse antibiotic drug interactions. Drugs 20, 57–68 (1980).

    Google Scholar 

  8. Moore, T. J., Crantz, T. R., Hollenberg, N. K., Koletsky, R. J., Leboff, M. S., Swartz, S. L., Levine, L., Podolsky, S., Dluhy, R. G., and Williams, G. H.: Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension 3, 168–173 (1981).

    Google Scholar 

  9. Durao, V., Prata, M. M., and Goncalves, L. M. P.: Modification of antihypertensive effect of β-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis. Lancet II, 1005–1007 (1977).

    Google Scholar 

  10. Durao, V., and Rico, J. M. G. T.: Modification by indomethacin of the blood pressure lowering effect of pindolol and propranolol in conscious rabbits. Eur. J. Pharmac. 43, 377–381 (1977).

    Google Scholar 

  11. Easton, P. A., and Koval, A.: Hypertensive reaction with sulindac. Can. Med. Ass. J. 122, 1273–1274 (1980).

    Google Scholar 

  12. Lopez-Ovejero, J. A., Weber, M. A., Drayer, J. I. M., Sealey, J. E., and Laragh, J. H.: Effects of indomethacin alone and during diuretic or P-adren- oreceptorblockade therapy on blood pressure and the renin system in essential hypertension. Clin. Sci. Mol. Med. 55, 203–205 (1978).

    Google Scholar 

  13. Chennavasin, P., Seiwell, R., and Brater, D. C.: Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. J. Pharmac. Exp.Ther. 275, 77–81 (1980).

    Google Scholar 

  14. Patak, R. V., Mookerjee, B. K., Bentzel, C. J., Hysert, P. E., Bagej, M., and Lee, J. B.: Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man. Prostaglandins 10, 649–659 (1975).

    Google Scholar 

  15. Binnion, P. F.: Drug interactions with digitalis glycosides. Drugs 15, 369–380 (1978).

    Google Scholar 

  16. Brown, D. D., Spector, R., and Juhl, R. P.: Drug interactions with digoxin. Drugs 20, 198–206 (1980).

    Google Scholar 

  17. Boura, A. L. A., and Green, A. F.: Adrenergic neurone blockade and other acute effects caused by N-benzyl-N′-N″-dimethylguanidine and its orthochloro derivative. Br. J. Pharmac. 20, 36–55 (1963).

    Google Scholar 

  18. Burn, J. H., and Rand, M. J.: The action of sympathomimetic amines in animals treated with reserpine. J. Physiol. 144, 314–336 (1958).

    Google Scholar 

  19. Pickering, I. K., and Rutherford, I.: Effect of concentration and time upon inactivation of tobramycin, gentamicin, netilmicin and amikacin by azlocil- lin, carbenicillin, mecillinam, mezlocillin and piperacillin. J. Pharmac. Exp. Ther. 217, 345–349 (1981).

    Google Scholar 

  20. Thompson, M. J. B., Russo, M. E., Saxon, B. J., Atkinthor, E., and Matsen, J. M.: Gentamicin inactivation by piperacillin or carbenicillin in patients with end stage renal disease. Antimicrob. Ag. Chemother. 21, 268–273 (1982).

    Google Scholar 

  21. Weibert, R., Keane, W., and Shapiro, F.: Carbenicillin inactivation of amin¬oglycosides in patients with severe renal failure. Trans. Am. Soc. Artif. Intern. Organs 22, 439–443 (1976).

    Google Scholar 

  22. Brown, D. D., and Juhl, R. P.: Decreased bioavailability of digoxin due to antacids and kaolin pectin. N. Engl. J. Med. 295, 1034–1037 (1976).

    Google Scholar 

  23. Dobbs, J. H., Skoutakis, V. A., Acchardio, S. R., and Dobbs, B. R.: Effects of aluminum hydroxide on the absorption of propranolol. Curr. Ther. Res. 21, 887–892 (1977).

    Google Scholar 

  24. Garty, M., and Hurwitz, A.: Effect of cimetidine and antacids on intestinal absorption of tetracycline. Clin. Pharmac. Ther. 28, 203–207 (1980).

    Google Scholar 

  25. Khalil, S. A. H.: Bioavailability of digoxin in presence of antacids. J. Pharm. Sci. 63,1641–1642 (1974) (letter).

    Google Scholar 

  26. Wood, A. J. J., and Feely, J.: Pharmacokinetic drug interactions with propranolol. Clin. Pharmacokin. 8, 253–262 (1983).

    Google Scholar 

  27. Robinson, D. S., Benjamin, D. M., and McCormack, J. J.: Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin. Pharmac. Ther. 12, 491–495 (1971).

    Google Scholar 

  28. Ambre, J. J., and Fisher, L. J.: Effect of coadministration of aluminum and magnesium hydroxides on absorption of anticoagulants in man. Clin. Pharmac. Ther. 14, 231–238 (1973).

    Google Scholar 

  29. Neuvonen, P. J., Elfring, S. M., and Elonen, E.: Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man. Eur. J. Clin. Pharmac. 13, 213–218 (1978).

    Google Scholar 

  30. Albert, K. S., Ayres, J. W., DiSanto, A. R., Weidler, D. I., Sakmar, E., Hall¬mark, M. R., Stoll, R. G., Desante, K. A., and Wagner, J. G.: Influence of kaolin-pectin suspension on digoxin bioavailability. J. Pharm. Sci. 1, 1582–1586 (1978).

    Google Scholar 

  31. Brown, D. D., Juhl, R. P., and Warner, S. L.: Decreased bioavailability of digoxin due to hypocholesterolemia interventions. Circulation 58, 164–172 (1978).

    Google Scholar 

  32. Caldwell, J. H., and Greenberger, N. J.: Interruption of the enterohepatic circulation of digitoxin by cholestyramine. I. Protection against lethal digitoxin intoxication. J. Clin. Invest. 50, 2626–2637 (1971).

    Google Scholar 

  33. Jahnchen, E., Meinertz, T., Gilfrich, H.-J., Kersting, F., and Groth, V.: Enhanced elimination of warfarin during treatment with cholestyramine. Br. J. Clin. Pharmac. 5, 437–440 (1978).

    Google Scholar 

  34. Mungall, D., Talbert, R. L., Phillips, C., Jaffe, D., and Ludden, T. M.: Sucralfate and warfarin. Ann. Intern. Med. 98, 557 (1983) (letter).

    Google Scholar 

  35. Levine, R. R.: Factors affecting gastrointestinal absorption of drugs. Digest Dis. 15, 171–188 (1970).

    Google Scholar 

  36. Nimmo, W. S., Heading, R. C., Wilson, J., Tothill, P., and Prescott, L. F.: Inhibition of gastric emptying and drug absorption by narcotic analgesics. Br. J. Clin. Pharmac. 2, 509–513 (1975).

    Google Scholar 

  37. Garnett, W. R., Carter, B. L., and Bellock, J. M.: Bioavailability of phenytoin administered with antacids. Ther. Drug Monitoring 1, 435–437 (1979).

    Google Scholar 

  38. Kulshrestha, V. K., Thomas, M., Wadsworth, J., and Richens, A.: Interaction of phenytoin and antacids. Br. J. Clin. Pharmac. 6, 177–179 (1978).

    Google Scholar 

  39. Manninen, V., Apajalahti, A., Simonen, H., and Reissel, P.: Effect of propantheline and metoclopramide on absorption of digoxin. Lancet I, 398 (1973).

    Google Scholar 

  40. Pond, S. M., Graham, G. G., Brikett, D. J., and Wade, D. N.: Effects of tricyclic antidepressants on drug metabolism. Clin. Pharmac. Ther. 18, 191–199 (1975).

    Google Scholar 

  41. Juhl, R. P., Summers, R. W., Guillory, J. K., Blang, S. M., Cheng, F. H., and Brown, D. D.: Effect of sulfasalazine on digoxin bioavailability. Clin. Pharmac. Ther. 20, 387–394 (1976).

    Google Scholar 

  42. Lindenbaum, J., Maulitz, R. M., and Butler, V. P.: Inhibition of digoxin absorption by neomycin. Gastroenterology 71, 399–404 (1976).

    Google Scholar 

  43. Lindenbaum, J., Rund, D. H., Butler, V. P., Tse-Eng, D., and Saha, J. R.: Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. N. Engl. J. Med. 305, 789–794 (1981).

    Google Scholar 

  44. Fine, A., Henderson, I. S., Morgan, D. R., and Wilstone, W. J.: Malabsorption of furosemide caused by phenytoin. Br. Med. J. 2, 1061–1062 (1977).

    Google Scholar 

  45. Koch-Weser, J., and Sellers, E. M.: Binding of drugs to serum albumin. N. Engl. J. Med. 294, 311–316, 526–531 (1976).

    Google Scholar 

  46. Koch-Weser, J., and Sellers, EM.: Binding of drugs to serum albumin. N. Engl. J. Med. 294, 311–316, 526–531 (1976)

    Google Scholar 

  47. Aggeler, P. M., O’Reilly, R. A., and Leong, L.: Potentiation of anticoagulant effect of warfarin by phenylbutazone. N. Engl. J. Med. 276, 496–501 (1967).

    Google Scholar 

  48. Bjornsson, T. D., Meffin, P. J., Swezey, S., and Blaschke, T. F.: Clofibrate displaces warfarin from plasma proteins in man: An example of a pure displacement interaction. J. Pharmac. Exp. Ther. 210,, 316–321 (1979).

    Google Scholar 

  49. MacLeod, S. M., and Sellers, E. M.: Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants. Drugs 11, 461–470 (1976).

    Google Scholar 

  50. Sellers, E. M., and Koch-Weser, J.: Potentiation of warfarin-induced hypo- prothombinemia by chloral hydrate. N. Engl. J. Med. 283, 827–831 (1970).

    Google Scholar 

  51. Udall, J. A.: Warfarin-chloral hydrate interaction. Pharmacological activity and clinical significance. Ann. Intern. Med. 81, 341–344 (1974).

    Google Scholar 

  52. Sellers, E. M., and Koch-Weser, J.: Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clin. Pharmac. Ther. 11, 524–529 (1970).

    Google Scholar 

  53. Hansen, J. M., Siersbaek-Nielsen, K., Kristensen, M., Skousted, L., and Christensen, L. K.: Effects of diphenylhydantoin on the metabolism of di- coumarol in man. Acta Med. Scand. 189, 15–19 (1971).

    Google Scholar 

  54. Neuvonen, P. J., Lehtovaara, R., Bardy, A., and Elonen, E.: Antipyrine analgesics in patients on antiepileptic drug therapy. Eur. J. Clin. Pharmac. 15, 263–268 (1979).

    Google Scholar 

  55. Fraser, D. G., Ludden, T. M., Evens, R. P., and Sutherland, E.W.: Displacement of phenytoin from plasma binding sites by salicylate. Clin. Pharmac. Ther. 27, 165–169 (1980).

    Google Scholar 

  56. Wesseling, H., Mols-Thurkow, I.: Interaction of diphenylhydantoin (DPH) and tolbutamide in man. Eur. J. Clin. Pharmac. 8, 75–78 (1975).

    Google Scholar 

  57. Mattson, R. H., Cramer, J. A., Williamson, P. C., and Novelly, R. A.: Valproic acid in epilepsy: Clinical and pharmacological effects. Ann. Neurol. 3, 20–25 (1978).

    Google Scholar 

  58. Perucca, E., Hebdige, S., Gatti, G., Leccini, S., Frigo, B. M., and Crema, A.: Interaction between phenytoin and valproic acid: Plasma protein binding and metabolic effects. Clin. Pharmac. Ther. 28, 779–789 (1980).

    Google Scholar 

  59. Burns, J. J., and Conney, A. H.: Enzyme stimulation and inhibition in the metabolism of drugs. Proc. R. Soc. Med. 58, 955–960 (1965).

    Google Scholar 

  60. Gelehrter, TD .: Enzyme induction. N. Engl. J. Med. 294, 522–526, 589–595, 646–651 (1976)

    Google Scholar 

  61. Gelehrter, TD .: Enzyme induction. N. Engl. J. Med. 294, 522–526, 589–595, 646–651 (1976)

    Google Scholar 

  62. Gelehrter, TD .: Enzyme induction. N. Engl. J. Med. 294, 522–526, 589–595, 646–651 (1976)

    Google Scholar 

  63. Buchanan, R. A., Heffelfinger, J. C., and Weiss, C. F.: The effect of pheno barbital on diphenylhydantoin metabolism in children. Pediatrics 43, 114–116 (1969).

    Google Scholar 

  64. Hansen, J. M., Siersbaek-Nielsen, K., and Skovsted, L.: Carbamazepine-in- duced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin. Pharmac. Ther. 12, 539–543 (1971).

    Google Scholar 

  65. Kutt, H., Haynes, J., Verebely, K., and McDowell, F.: The effect of pheno- barbital on plasma diphenylhydantoin level and metabolism in man and in rat liver microsomes. Neurology 19, 611–616 (1969).

    Google Scholar 

  66. Perucca, E.: Pharmacokinetic interactions with antiepileptic drugs. Clin. Pharmacokin. 7, 57–84 (1982).

    Google Scholar 

  67. Perucca, E., and Richens, A.: Drug interactions with phenytoin. Drugs 21, 120–137 (1981).

    Google Scholar 

  68. Cucinell, S. A., Conney, A. H., Sansur, M., and Burns, J. J.: Drug interac¬tions in man. I. Lowering effect of phenobarbital on plasma levels of bishy- droxycoumarin (Dicumarol) and diphenylhydantoin (Dilantin). Clin. Pharmac. Ther. 6, 420–429 (1965).

    Google Scholar 

  69. Koch-Weser, J., and Sellers, E. M.: Drug interactions with coumarin anticoagulants. N. Engl. J. Med. 285, 487–498, 547–558 (1971).

    Google Scholar 

  70. Koch-Weser, J., and Sellers, E. M.: Drug interactions with coumarin anticoagulants. N. Engl. J. Med. 285, 487–498, 547–558 (1971).

    Google Scholar 

  71. O’Reilly, R. A.: Interaction of chronic daily warfarin therapy and rifampin. Ann. Intern. Med. 83, 506–508 (1975).

    Google Scholar 

  72. O’Reilly, R. A.: Interaction of sodium warfarin and rifampin. Ann. Intern. Med. 81, 337–340 (1974).

    Google Scholar 

  73. Romankiewicz, J. A., and Ehrman, M.: Rifampin and warfarin: A drug interaction. Ann. Intern. Med. 82, 224–225 (1975).

    Google Scholar 

  74. Dossing, M., Pilsgaard, H., Rasmussen, B., and Poulsen, H. E.: Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. Eur. J. Clin. Pharmac. 25, 215–222 (1983).

    Google Scholar 

  75. Data, J. L., Wilkinson, G. R., and Nies, A. S.: Interaction of quinidine with anticonvulsant drugs. N. Engl. J. Med. 294, 699–702 (1976).

    Google Scholar 

  76. Urbano, A. M.: Phenytoin-quinidine interaction in a patient with recurrent ventricular tachyarrhythmias. N. Engl. J. Med. 308, 225 (1983) (letter).

    Google Scholar 

  77. Kroboth, F. J., Kroboth, P. D., and Logan, T.: Phenytoin-theophylline- quinidine interaction. N. Engl. J. Med. 308,725 (1983) (letter).

    Google Scholar 

  78. Jaillon, P., and Kates, R. E.: Phenytoin-induced changes in quinidine and 3-hydroxyquinidine pharmacokinetics in conscious dogs. J. Pharmac. Exp. Ther. 213, 33–37 (1980).

    Google Scholar 

  79. Twum-Barima, Y., Carruthers, S. G.: Quinidine-rifampin interaction. N. Engl. J. Med. 304, 1466–1469 (1981).

    Google Scholar 

  80. Solomon, H. M., and Abrams, W. B.: Interactions between digitoxin and other drugs in man. Am. Heart J. 83, 277–280 (1972).

    Google Scholar 

  81. Solomon, H. M., Reich, S., Spirt, N., and Abrams, W. B.: Interactions between digitoxin and other drugs in vitro and in vivo. Ann. N.Y. Acad. Sci. 179, 362–370 (1971).

    Google Scholar 

  82. Pentikainen, P. J., Koivula, I. H., and Hiltunen, H. A.: Effect of rifampicin treatment on the kinetics of mexiletine. Eur. J. Clin. Pharmac. 23, 261–266 (1982).

    Google Scholar 

  83. Serlin, M. J., and Breckenridge, A. M.: Drug interactions with warfarin. Drugs 25, 610–620 (1983).

    Google Scholar 

  84. Mantyla, R., Mannisto, P., Nykanen, S., Koponen, A., and Lamminsivu, U.: Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. Eur. J. Clin. Pharmac. 24, 227–230 (1983).

    Google Scholar 

  85. Linnoila, M., Mattila, M. J., and Kitchell, B. S.: Drug interactions with alcohol. Drugs 18, 299–311 (1979).

    Google Scholar 

  86. Seixas, F. A.: Alcohol and its drug interactions. Ann. Intern. Med. 83, 86–92 (1975).

    Google Scholar 

  87. Sellers, E. M., and Holloway, M. R.: Drug kinetics and alcohol ingestion. Clin. Pharmacokin. 3, 440–452 (1978).

    Google Scholar 

  88. Karim, A., Nissen, C., and Azarnoff, D. L.: Clinical pharmacokinetics of disopyramide. J. Pharmacokin. Biopharm. 10, 465–494 (1982).

    Google Scholar 

  89. Reed, R. C., and Schwartz, H. J.: Phenytoin-theophylline-quinidine interaction. N. Engl. J. Med. 308, 724–725 (1983) (letter).

    Google Scholar 

  90. Marquis, J.-F., Carruthers, S. G., Spence, J. D., Brownstone, Y. S., and Toogood, J. H.: Phenytoin-theophylline interaction. N. Engl. J. Med. 307, 1189–1190 (1982).

    Google Scholar 

  91. Poor, D. M., Self, T. H., and Davis, H. L.: Interaction of rifampin and digitoxin. Arch. Intern. Med. 143, 599 (1983).

    Google Scholar 

  92. Branch, R. A., Shand, D. G., Wilkinson, G. R., and Nies, A. S.: The reduction of lidocaine clearance by dl-propranolol: An example of hemodynamic drug interaction. J. Pharmac. Exp. Ther. 184, 515–519 (1973).

    Google Scholar 

  93. Ochs, H. R., Carstens, G., and Greenblatt, D. J.: Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N. Engl. J. Med. 303, 373–377 (1980).

    Google Scholar 

  94. Conrad, K. A., Byers, J. M., Finley, P. R., and Burnham, L.: Lidocaine elimination: Effects of metoprolol and of propranolol. Clin. Pharmac. Ther. 33, 133–138 (1983).

    Google Scholar 

  95. Halkin, H., Meffin, P., Melmon, K. L., and Rowland, M.: Influence of congestive heart failure on blood levels of lidocaine and its active monode- ethylated metabolite. Clin. Pharmac. Ther. 17, 669–676 (1975).

    Google Scholar 

  96. Stenson, R. E., Constantino, R. T., and Harrison, D. C.: Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man. Circulation 43, 205–211 (1971).

    Google Scholar 

  97. Thomson, P. D., Melmon, K. L., Richardson, J. A., Cohn, K., Steinbrunn, W., Cudihee, R., and Rowland, M.: Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann. Intern. Med. 78, 499–508 (1973).

    Google Scholar 

  98. Feely, J., Wilkinson, G. R., McAllister, C. B., and Wood, A. J. J.: Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann. Intern. Med. 96, 592–594 (1982).

    Google Scholar 

  99. Knapp, A. B., Maguire, W., Keren, G., Karmen, A., Levitt, B., Miura, D. S., and Somberg, J.C.: The cimetidine-lidocaine interaction. Ann. Intern. Med. 98, 174–177 (1983).

    Google Scholar 

  100. Spahn, H., Mutschler, E., Kirch, W., Ohnhaus, E. E., and Janisch, H. D.: Influence of ranitidine on plasma metoprolol and atenolol concentrations. Br. Med. J. 286, 1546–1547 (1983).

    Google Scholar 

  101. Desmond, P. V., Mashford, M. L., Harman, P. J., Morphett, B. J., Breen, K. J., and Wang, Y. M.: Decreased oral warfarin clearance after ranitidine and cimetidine. Clin. Pharmac. Ther. 35, 338–341 (1984).

    Google Scholar 

  102. Daneshmend, T. K., and Roberts, C. J. C.: Cimetidine and bioavailability of labetalol. Lancet 1, 565 (1981) (letter).

    Google Scholar 

  103. Kirch, W., Kohler, H., Spahn, H., and Mutschler, E.: Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet 2, 531–532 (1981) (letter).

    Google Scholar 

  104. Reimann, I. W., Klotz, U., and Frolich, J. C.: Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics. Clin. Pharmac. Ther. 32, 749–757 (1982).

    Google Scholar 

  105. Latini, R., Tognoni, G., and Kates, R. E.: Clinical pharmacokinetics of am- iodarone. Clin. Pharmacokin. 9, 136–156 (1984).

    Google Scholar 

  106. Chiariello, M., Volpe, M., Rengo, F., Trimarco, B., Violini, R., Ricciardelli, B., and Condorelli, M.: Effect of furosemide on plasma concentration and p-blockade by propranolol. Clin. Pharmac. Ther. 26, 433–436 (1979).

    Google Scholar 

  107. Geaney, D. P., Carver, J. G., Davies, C. L., and Aronson, J. K.: Pharmacokinetic investigation of the interactions of azapropazone with phenytoin. Br. J. Clin. Pharmac. 15, 727–734 (1983).

    Google Scholar 

  108. Christensen, L. K., and Skovsted, L.: Inhibition of drug metabolism by chloramphenicol. Lancet 2, 1397–1399 (1969).

    Google Scholar 

  109. Koup, J. R., Gilbaldi, M., McNamara, P., Hilligoss, D. M., Colburn, W. A., and Bruck, E.: Interaction of chloramphenicol with phenytoin and pheno- barbital. Clin. Pharmac. Ther. 24, 571–575 (1978).

    Google Scholar 

  110. Eadie, M. J.: Anticonvulsant drugs: An update. Drugs 27, 328–363 (1984).

    Google Scholar 

  111. Vincent, F. M.: Phenothiazine-induced phenytoin intoxication. Ann. Intern Med. 93, 56–57 (1980) (letter).

    Google Scholar 

  112. Vestal, R. E., Kornhauser, D. M., Hollifield, J. W., and Shand, D. G.: Inhibition of propranolol metabolism by chlorpromazine. Clin. Pharmac. Ther. 25, 19–24 (1979).

    Google Scholar 

  113. Somogyi, A., and Gugler, R.: Drug interactions with cimetidine. Clin. Pharmacokin. 7, 23–41 (1982).

    Google Scholar 

  114. Neuvonen, P. J., Tokola, R. A., and Kaste, M.: Cimetidine-phenytoin interactions: Effect on serum phenytoin concentration and antipyrine test. Eur. J. Clin. Pharmac. 21, 215–220 (1981).

    Google Scholar 

  115. Bartle, W. R., Walker, S. E., and Shapero, T.: Dose-dependent effect of cimetidine on phenytoin kinetics. Clin. Pharmac. Ther. 33, 649–655 (1983).

    Google Scholar 

  116. Feely, J., Wilkinson, G. R., and Wood, A. J. J.: Reduction of liver blood flow and propranolol metabolism by cimetidine. N. Engl. J. Med. 304, 692–695 (1981).

    Google Scholar 

  117. Hardy, B. G., Zador, I. T., Golden, L., Lalka, D., and Schentag, J. J.: Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. Am. J. Cardiol. 52, 172–175 (1983).

    Google Scholar 

  118. Haworth, E., and Burroughs, A. K.: Disopyramide and warfarin interaction. Br. Med. J. 2, 866–867 (1977).

    Google Scholar 

  119. Kiorboe, E.: Phenytoin intoxication during treatment with Antabuse® (dis ulfiram). Epilepsia 7, 246–249 (1966).

    Google Scholar 

  120. Olesen, O. V.: Disulflramum (Antabuse®) as inhibitor of phenytoin metabolism. Acta Pharmac. Tox. 24, 317–322 (1966).

    Google Scholar 

  121. O’Reilly, R. A.: Interaction of sodium warfarin and disulfiram (Antabuse®) in man. Ann. Intern. Med. 78, 73–76 (1973).

    Google Scholar 

  122. Kutt, H., Verebely, K., and McDowell, F.: Inhibition of diphenylhydantoin metabolism in rats and in rat liver microsomes by antitubercular drugs. Neurology 18, 706–710 (1968).

    Google Scholar 

  123. Murray, F. J.: Outbreak of unexpected reactions among epileptics taking isoniazid. Am. Rev. Resp. Dis. 86, 729–732 (1962).

    Google Scholar 

  124. Garrettson, L. K., Perel, J. M., and Dayton, P. G.: Methylphenidate interaction with both anticonvulsants and ethyl biscoumacetate. J. Am. Med. Ass. 207, 2053–2056 (1969).

    Google Scholar 

  125. O’Reilly, R. A.: The stereoselective interaction of warfarin and metronidazole in man. N. Engl. J. Med. 295, 354–357 (1976).

    Google Scholar 

  126. DeTeresa, E., Vera, A., Ortigosa J., Pulpon, L. A., Arus, A. P., and DeArtaza, M.: Interaction between anticoagulants and contraceptives: an unsuspected finding. Br. Med. J. 2, 1260–1261 (1979).

    Google Scholar 

  127. O’Reilly, R. A.: Phenylbutazone and sulfinpyrazone interaction with oral anticoagulant phenprocoumon. Arch. Intern. Med. 142, 1634–1637 (1982).

    Google Scholar 

  128. Solomon, H. M., and Schrogie, J. J.: The effect of phenyramidol on the metabolism of diphenlhydantoin. Clin. Pharmac. Ther. 8, 554–556 (1967).

    Google Scholar 

  129. Abernethy, D. R., Greenblatt, D. J., Steel, K., and Shader, R.I.: Impairment of hepatic drug oxidation by propoxyphene. Ann. Intern. Med. 97, 223–224 (1982).

    Google Scholar 

  130. Kabins, S. A.: Interactions among antibiotics and other drugs. J. Am. Med. Ass. 219, 206–212 (1972).

    Google Scholar 

  131. Lumholtz, B., Siersbaek-Nielsen, K., Skovsted, L., Kampmann, J., and Hansen, J. M.: Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism. Clin. Pharmac. Ther. 17, 731–734 (1975).

    Google Scholar 

  132. Hansen, J. M., Kristensen, M., and Skovsted, L.: Sulthiame (Opsollot®) as inhibitor of diphenylhydantoin metabolism. Epilepsia 9, 17–22 (1968).

    Google Scholar 

  133. Wormser, G. P., Keusch, G. T., and Heel, R. C.: Co-trimoxazole (trimetho-prim-sulfamethoxazole). An updated review of its antibacterial activity and clinical efficacy. Drugs 24, 459–518 (1982).

    Google Scholar 

  134. O’Reilly, R. A.: Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N. Engl. J. Med. 302, 33–35 (1980).

    Google Scholar 

  135. O’Reilly, R. A., and Motley, C. H.: Racemic warfarin and trimethoprim- sulfamethoxazole interaction in humans. Ann. Intern. Med. 91, 34–36 (1979).

    Google Scholar 

  136. Levy, R. H., and Koch, K. M.: Drug interactions with valproic acid. Drugs 24, 543–556 (1982).

    Google Scholar 

  137. LaDu, B. N.: Pharmacogenetics. Med. Clin. North Am. 53, 839–855 (1969).

    Google Scholar 

  138. Vesell, E.: Introduction: Genetic and environment factors affecting drug response in man. Fed. Proc. 31, 1253–1269 (1972).

    Google Scholar 

  139. Weber, W. W.: The relationship of genetic factors to drug reactions.In: Drug-induced diseases, Vol. 4. L. Heyler, N. M. Peck, eds. Excerpta Medica, Amsterdam 1972.

    Google Scholar 

  140. Evans, D. A. A., Mantey, K. A., and McKusick, V. A.: Genetic control of isoniazid metabolism in man. Br. Med. J. 2, 485–491 (1960).

    Google Scholar 

  141. Kutt, H., Brennan, R., Dehejia, H., and Verebely, K.: Diphenylhydantoin intoxication. A complication of isoniazid therapy. Am. Rev. Resp. Dis. 101, 377–384 (1970).

    Google Scholar 

  142. Kutt, H., Wolk, M., Scherman, R., and McDowell, F.: Insufficient para- hydroxylation as a cause of diphenylhydantoin toxicity. Neurology 14, 542–548 (1964).

    Google Scholar 

  143. Vasko, M. R., Bell, R. D., Daly, D. D., and Pippenger, C. E.: Inheritance of phenytoin hypometabolism: A kinetic study of one family. Clin. Pharmac. Ther. 27, 96–103 (1980).

    Google Scholar 

  144. Sjoqvist, F.: Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc. R. Soc. Med. 58, 967–977 (1965).

    Google Scholar 

  145. DeVita, V. T., Hahn, M. A., and Oliverio, V. T.: Monoamine oxidase inhibition by a new carcinostatic agent, N-isopropyl-A-(2-methyl-hydrazino)-p- to-luamide (MIH). Proc. Soc. exp. Biol. Med. 120, 561–565 (1965).

    Google Scholar 

  146. Lejonc, J. L., Gusmini, D., and Brochard, P.: Isoniazid and reaction to cheese. Ann. Intern. Med. 91, 793 (1979) (letter).

    Google Scholar 

  147. Smith, C. K., and Durack, D. T.: Isoniazid and reaction to cheese. Ann. Intern. Med. 88, 520–521 (1978).

    Google Scholar 

  148. Berg, M. J., Berlinger, W. G., Goldberg, M. J., Spector, R., and Johnson, G. F.: Acceleration of the body clearance of phenobarbital by oral activated charcoal. N. Engl. J. Med. 307, 642–644 (1982).

    Google Scholar 

  149. Levy, G.: Gastrointestinal clearance of drugs with activated charcoal. N. Engl. J. Med. 307, 676–678 (1982) (editorial).

    Google Scholar 

  150. duSouich, P., Caille, G., and Larochelle, P.: Enhancement of nadolol elimination by activated charcoal and antibiotics. Clin. Pharmac. Ther. 33, 585–590 (1983).

    Google Scholar 

  151. Carruthers, S. G., and Dujovne, C. A.: Cholestyramine and spironolactone and their combination in digitoxin elimination. Clin. Pharmac. Ther. 27, 184–187 (1980).

    Google Scholar 

  152. McAllister, R. G., Howell, S. M., Gomer, M. S., and Selby, J. B.: Effect of intravenous furosemide on the renal excretion of digoxin. J. Clin. Pharmac. 16, 110–117 (1976).

    Google Scholar 

  153. Semple, P., Tilstone, W. J., and Lawson, D. H.: Furosemide and urinary digoxin clearance. N. Engl. J. Med. 293, 612–613 (1971) (letter).

    Google Scholar 

  154. Tilstone, W. J., Semple, P. F., Lawson, D. H., and Boyle, J. A.: Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin. Clin. Pharmac. Ther. 22, 389–394 (1977).

    Google Scholar 

  155. Prescott, L. F.: Mechanisms of renal excretion of drugs. Br. J. Anaesth. 44, 246–251 (1972).

    Google Scholar 

  156. Rennick, B. R.: Renal excretion of drugs: Tubular transport and metabolism. Ann. Rev. Pharmac. 12, 141–156 (1972).

    Google Scholar 

  157. Weiner, I. M., and Mudge, G. J.: Renal tubular mechanisms for excretion of organic acids and bases. Am. J. Med. 36, 743–762 (1964).

    Google Scholar 

  158. Rose, H. J., Pruitt, A. W., and McNay, J. L.: Effect of experimental azotemia on renal clearance of furosemide in the dog. J. Pharmac. Exp. Ther. 196, 238–247 (1976).

    Google Scholar 

  159. Rose, H. J., Pruitt, A. W., Dayton, P. G., and McNay, J. L.: Relationship of urinary furosemide excretion rate to natriuretic effect in experimental azotemia. J. Pharmac. Exp. Ther. 199, 490–497 (1976).

    Google Scholar 

  160. Rose, H. J., O’Malley, K., and Pruitt, A. W.: Depression of renal clearance of furosemide in man by azotemia. Clin. Pharmac. Ther. 21, 141–146 (1976).

    Google Scholar 

  161. Rennick, B. R.: Renal tubule transport of organic cations. Am. J. Physiol. 240, F83–F89 (1981).

    Google Scholar 

  162. McKinney, T. D.: Heterogeneity of organic base secretion by proximal tubules. Am. J. Physiol. 243, F404–F407 (1982).

    Google Scholar 

  163. Somogyi, A., McLean, A., and Heinzow, B.: Cimetidine-procainamide pharmacokinetic interaction in man: Evidence of competition for tubular secretion of basic drugs. Eur. J. Clin. Pharmacol 25, 339–345 (1983).

    Google Scholar 

  164. Belz, G. G., Doering, W., Aust, P. E., Heinz, M., Matthews, J., and Schneider, B.: Quinidine-digoxin interaction. Cardiac efficacy of elevated serum digoxin concentration. Clin. Pharmac. Ther. 31, 548–554 (1982).

    Google Scholar 

  165. Bigger, J. T., and Leahey, E. B.: Quinidine and digoxin. An important interaction. Drugs 24, 229–239 (1982).

    Google Scholar 

  166. Bigger, J. T.: The quinidine-digoxin interaction. What do we know about it? N. Engl. J. Med. 301, 779–781 (1979) (editorial).

    Google Scholar 

  167. Chen, T.-S., and Friedman, H. S.: Alteration of digoxin pharmacokinetics by a single dose of quinidine. J. Am. Med. Ass. 244, 669–672 (1980).

    Google Scholar 

  168. Das, G., Krishnamurthi, S., Barr, C., Carlson, J., and Khalil, S.: Clinical implications of digoxin-quinidine interaction in man. Clin. Res. 29, 691A (1981) (abstract).

    Google Scholar 

  169. Doering, W.: Quinidine-digoxin interaction. Pharmacokinetics, underlying mechanism and clinical implications. N. Engl. J. Med. 301, 400–404 (1979).

    Google Scholar 

  170. Hager, W. D., Fenster, P., Mayersohn, M., Perrier, D., Graves, P., Marcus, F.I., and Goldman, S.: Digoxin-quinidine interaction. Pharmacokinetic evaluation. N. Engl. J. Med. 300, 1238–1241 (1979).

    Google Scholar 

  171. Hirsh, P. D., Weiner, H. J., and North, R. L.: Further insights into digoxin- quinidine interaction: Lack of correlation between serum digoxin concentration and inotropic state of the heart. Am. J. Cardiol. 46, 863–867 (1980).

    Google Scholar 

  172. Holt, D. W., Hayler, A. M., Edmonds, M. E., and Ashford, R. F.: Clinically significant interaction between digoxin and quinidine. Br. Med. J. 2, 1401 (1979).

    Google Scholar 

  173. Leahey, E. B.: Digoxin-quinidine interaction: Current status. Ann. Intern. Med. 93, 775–776 (1980) (editorial).

    Google Scholar 

  174. Leahey, E. B., Rieffel, J. A., Drusin, R. E., Heissenbuttel, R. H., Lovejoy, W. P., and Bigger, J. T.: Interaction between quinidine and digoxin. J. Am. Med. Ass. 240, 533–534 (1978).

    Google Scholar 

  175. Leahey, E. B., Reiffel, J. A., Giardina, E.-J. V., and Bigger, J. T.: The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin. Ann. Intern. Med. 92, 605–608 (1980).

    Google Scholar 

  176. Leahey, E. B., Reiffel, J. A., Heissenbuttel, R. H., Drusin, R. E., Lovejoy, W. P., and Bigger, J. T.: Enhanced cardiac effect of digoxin during quinidine treatment. Arch. Intern. Med. 139, 519–521 (1979).

    Google Scholar 

  177. Mungall, D. R., Robichaux, R. P., Perry, W., Scott, J. W., Robinson, A., Burelle, T., and Hurst, D.: Effects of quinidine on serum digoxin concentration. Ann. Intern. Med. 93, 689–693 (1980).

    Google Scholar 

  178. Schenck-Gustafsson, K., Jogestrand, T., Nordlander, R., and Dahlqvist, R.: Effect of quinidine on digoxin concentration in skeletal muscle and serum in patients with atrial fibrillation. Evidence for reduced binding of digoxin in muscle. N. Engl. J. Med. 305, 209–211 (1981).

    Google Scholar 

  179. Steiness, E., Waldorff, S., Hansen, P. B., Kjaergard, H., Buch, J., and Egeblad, H.: Reduction of digoxin-induced inotropism during quinidine administration. Clin. Pharmac. Ther. 27, 791–795 (1980).

    Google Scholar 

  180. Williams, J. F., and Mathew, B.: Effect of quinidine on positive inotropic action of digoxin. Am. J. Cardiol. 47, 1052–1055 (1981).

    Google Scholar 

  181. Fenster, P. E., Hager, W. D., Perrier, D., Powell, J. R., Graves, P. E., and Michael, U. F.: Digoxin-quinidine interaction in patients with chronic renal failure. Circulation 66, 1277–1279 (1982).

    Google Scholar 

  182. Fichtl, B., and Doering, W.: The quinidine-digoxin interaction in perspective. Clin. Pharmacokin. 8, 137–154 (1983).

    Google Scholar 

  183. Belz, G. G., Doering, W., Munkes, R., and Matthews, J.: Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin. Pharmac. Ther. 33, 410–417 (1983).

    Google Scholar 

  184. Walker, A. M., Cody, R. J., Greenblatt, D. J., and Jick, H.: Drug toxicity in patients receiving digoxin and quinidine. Am. Heart J. 105, 1025–1028 (1983).

    Google Scholar 

  185. Schenck-Gustafsson, K., Jogestrand, T., Brodin, L.-A., Nordlander, R., and Dahlqvist, R.: Cardiac effects of treatment with quinidine and digoxin, alone and in combination. Am. J. Cardiol. 51, 777–782 (1983).

    Google Scholar 

  186. Das, G., Barr, C. E., and Carlson, J.: Reduction of digoxin effect during the digoxin-quinidine interaction. Clin. Pharmac. Ther. 35, 317–321 (1984).

    Google Scholar 

  187. Gibson, T. P., and Quintanilla, A.: Effect of quinidine on the renal handling of digoxin. J. Lab. Clin. Med. 96, 1062–1070 (1980).

    Google Scholar 

  188. Fenster, P. E., Powell, J. R., Graves, P. E., Conrad, K. A., Hager, W. D., Goldman, S., and Marcus, F. I.: Digitoxin-quinidine interaction: Pharmacokinetic evaluation. Ann. Intern. Med. 93, 698–701 (1980).

    Google Scholar 

  189. Garty, M., Sood, P., and Rollins, D. E.: Digitoxin elimination reduced during quinidine therapy. Ann. Intern. Med. 94, 35–37 (1981).

    Google Scholar 

  190. Ochs, H. R., Pabst, J., Greenblatt, D. J., and Dengler, H. J.: Noninteraction of digitoxin and quinidine. N. Engl. J. Med. 303, 672–674 (1980).

    Google Scholar 

  191. Schwartz, J. B., Keefe, D., Kates, R. E., and Harrison, D. C.: Verapamil and digoxin: Another drug-drug interaction. Clin. Res. 29, 501A (1981) (abstract).

    Google Scholar 

  192. Waldorff, S., Andersen, J. D., Heeboll-Neilsen, N., Nielsen, O. G., Moltke, E., Sorensen, U., and Steiness, E.: Spironolactone-induced changes in digoxin kinetics. Clin. Pharmac. Ther. 24, 162–167 (1978).

    Google Scholar 

  193. Wandell, M., Powell, J. R., Hager, W. D., Fenster, P. E., Graves, P. E., Conrad, K. A., and Goldman, S.: Effect of quinine on digoxin kinetics. Clin. Pharmac. Ther. 28, 425–430 (1980).

    Google Scholar 

  194. Pedersen, K. E., Christiansen, B. D., Kjaer, K., Klitgaard, N. A., and Nielsen-Kudsk, F.: Verapamil-induced changes in digoxin kinetics and intraerythrocytic sodium concentration. Clin. Pharmac. Ther. 34, 8–13 (1983).

    Google Scholar 

  195. Klein, H. O., Lang, R., Weiss, E., Segni, E. D., Libhaber, C., Guerrero, J., and Kaplinsky, E.: The influence of verapamil on serum digoxin concentration. Circulation 65, 998–1003 (1982).

    Google Scholar 

  196. Waldorff, S., Hansen, P. B., Egeblad, H., Berning, J., Buch, J., Kjaergard, H., and Steiness, E.: Interactions between digoxin and potassiumsparing diuretics. Clin. Pharmac. Ther. 33, 418–423 (1983).

    Google Scholar 

  197. Pedersen, K. E., Dorph-Pedersen, A., Hvidt, S., Klitgaard, N. A., Kjaer, K., and Nielsen-Kudsk, F.: Effect of nifedipine on digoxin kinetics in healthy subjects. Clin. Pharmac. Ther. 32, 562–565 (1982).

    Google Scholar 

  198. Gibson, T. P., and Quintanilla, A. P.: Effect of volume expansion and furosemide diuresis on the renal clearance of digoxin. J. Pharmac. Exp. Ther. 219, 54–59 (1981).

    Google Scholar 

  199. Boullin, D. J.: The action of antidepressants on the effects of other drugs. Primary Care 2, 669–688 (1975).

    Google Scholar 

  200. Stafford, J. R., and Fann, W. E.: Drug interactions with guanidinium antihypertensives. Drugs 13, 57–64 (1977).

    Google Scholar 

  201. Cocco, G., and Ague, C.: Interactions between cardioactive drugs and antidepressants. Eur. J. Clin. Pharmac. 11, 389–393 (1977).

    Google Scholar 

  202. Boakes, A. J., Laurence, D. R., Teoh, P. C., Barar, F. S. K., Benedikter, L. T., and Prichard, B. N. C.: Interactions between sympathomimetic amines and antidepressant agents in man. Br. Med. J. 7, 311–315 (1973).

    Google Scholar 

  203. Allum, W., Aminu, J., Bloomfield, T. H., Davies, C., Scales, A. H., and Vere, D. W.: Interaction between debrisoquin and phenylephrine in man. Br. J. Clin. Pharmac. 7, 51–57 (1974).

    Google Scholar 

  204. Hanahoe, T. H. P., Ireson, J. D., and Large, B. J.: Interactions between guanethidine and inhibitors of noradrenaline uptake. Arch. Int. Pharmacodyn. 182, 349–353 (1969).

    Google Scholar 

  205. Leishman, A. W. D., Matthews, H. L., and Smith, A. J.: Antagonism of gua- nethidine by imipramine. Lancet 7, 112 (1963).

    Google Scholar 

  206. Mitchell, J. R., Arias, L., and Oates, J. A.: Antagonism of the antihyperten¬sive action of guanethidine sulfate by desipramine hydrochloride. J. Am. Med. Ass. 202, 973–976 (1967).

    Google Scholar 

  207. Mitchell, J. R., Cavanaugh, J. H., Arias, L., and Oates, J. A.: Guanethidine and related agents. III. Antagonism by drugs which inhibit the norepinephrine pump in man. J. Clin. Invest. 49, 1596–1604 (1970).

    Google Scholar 

  208. Skinner, C., Coull, D. C., and Johnston, A. W.: Antagonism of the hypotensive action of bethanidine and debrisoquin by tricyclic antidepressants. Lancet 2, 564–566 (1969).

    Google Scholar 

  209. Stone, C. A., Porter, C. C., Stavorski, J. M., Ludden, C. T., and Totaro, J. A.: Antagonism of catecholamine-depleting agents by antidepressant and related drugs. J. Pharmac. 144, 196–204 (1964).

    Google Scholar 

  210. Gokhale, S. D., Gulati, O. D., and Udwadia, B. P.: Antagonism of the adrenergic neurone blocking action of guanethidine by certain antidepressant and antihistamine drugs. Arch. Int. Pharmacodyn. 160, 321–329 (1966).

    Google Scholar 

  211. Fann, W. E., Cavanaugh, J. H., and Kaufmann, J. S.: Doxepin: Effects on transport of biogenic amines in man. Psychopharmacologia 22, 111–125 (1972).

    Google Scholar 

  212. Chang, C. C., Costa, E., and Brodie, B. B.: Reserpine-induced release of drugs from sympathetic nerve endings. Life Sci. 3, 839–844 (1964).

    Google Scholar 

  213. Day, M. D.: Effect of sympathomimetic amines on the blocking action of guanethidine, bretylium, xylocholine. Br. J. Pharmac. 18, 421–439 (1962).

    Google Scholar 

  214. Day, M. D., and Rand, M. J.: Antagonism of guanethidine by dexampheta- mine and other related sympathomimetic amines. J. Pharm. Sci. 14, 541–549 (1962).

    Google Scholar 

  215. Day, M. D., and Rand, M. J.: Evidence for a competitive antagonism of guanethidine by dexamphetamine. Br. J. Pharmac. 20, 17–28 (1963).

    Google Scholar 

  216. Janowsky, D. S., El-Yousef, M. K., Davis, J. M., and Fann, W. E.: Antagonism of guanethidine by chlorpromazine. Am. J. Psychiat. 130, 808–812 (1973).

    Google Scholar 

  217. Misage, J. R., and McDonald, R. H.: Antagonism of hypotensive action of bethanidine by ‘common cold’ remedy. Br. Med. J. 2, 1–3 (1970).

    Google Scholar 

  218. Briant, R. H., Reid, J. L, and Dollery, C. T.: Interaction between clonidine and desipramine in man. Br. Med. J. 7, 522–523 (1973).

    Google Scholar 

  219. Hoobler, S. W., and Sagastume, E.: Clonidine hydrochloride in the treatment of hypertension. Am. J. Cardiol. 28, 67–83 (1971).

    Google Scholar 

  220. vanZwieten, P. A.: The reversal of clonidine-induced hypotension by protiptyline and desipramine. Pharmacology 14, 227–231 (1976).

    Google Scholar 

  221. McMurtry, R. J.: Propranolol, hypoglycemia, and hypertensive crisis. Ann. Intern. Med. 80, 669–670 (1974).

    Google Scholar 

  222. Nies, A. S., and Shand, D. G.: Hypertensive response to propranolol in a patient treated with methyl dopa - a proposed mechanism. Clin. Pharmac. Ther. 14, 823–826 (1973).

    Google Scholar 

  223. Prichard, B. N. C., and Ross, E. J.: Use of propranolol in conjunction with alpha receptor blocking drugs in pheochromocytoma. Am. J. Cardiol. 18, 394–398 (1966).

    Google Scholar 

  224. Bailey, R. R., and Neale, T. J.: Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockade. Br. Med. J. 7, 942–943 (1976).

    Google Scholar 

  225. Newton, R. W.: Physostigmine salicylate in the treatment of tricyclic antidepressant overdosage. J. Am. Med. Ass. 231, 941–944 (1974).

    Google Scholar 

  226. Noble, J., and Matthew, H.: Acute poisoning by antidepressants: Clinical features and management of 100 patients. Clin. Toxicol 2, 403–421 (1969).

    Google Scholar 

  227. Roberts, J., Ito, R., Reilly, J., and Carioli, V. J.: Influence of reserpine and beta TM 10 on digitalis induced ventricular arrhythmia. Circ. Res. 13, 149–158 (1963).

    Google Scholar 

  228. Arita, M., and Surawicz, B.: Electrophysiologic effects of phenothiazines on canine cardiac fibers. J. Pharmac. Exp. Ther. 184, 619–630 (1973).

    Google Scholar 

  229. Davis, J. M., Bartlett, E., and Termini, B. S.: Overdosage of psychotropic drugs. A review. Dis. Nerv. Syst. 29, 157–164 and 246–256 (1968).

    Google Scholar 

  230. Davis, JM., Bartlett, E., and Termini, BS.: Overdosage of psychotropic drugs. A review. Dis. Nerv. Syst. 29, 157–164 and 246–256 (1968)

    Google Scholar 

  231. Fowler, N. O., McCall, D., Chou, T., Holmes, J. C., and Hanenson, I. B.: Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am. J. Cardiol. 37, 223–230 (1976).

    Google Scholar 

  232. Williams, R. B., and Sherter, C.: Cardiac complications of tricyclic antide¬pressant therapy. Ann. Intern. Med. 74, 395–398 (1971).

    Google Scholar 

  233. Nash, C. W., and Heath, C.: Vascular responses to catecholamines during respiratory changes in pH. Am. J. Physiol. 200, 755–782 (1961).

    Google Scholar 

  234. Cumming, A. D., and Robertson, C.: Interaction between dispoyramide and practolol. Br. Med. J. 2, 1264 (1979).

    Google Scholar 

  235. Thornton, W. E.: Dementia induced by methyldopa with haloperidol. N. Engl. J. Med. 294, 1222 (1976).

    Google Scholar 

  236. MacCallum, W. A. G.: Interaction of lithium and phenytoin. Br. Med. J. 7, 610–611 (1980).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pharmacology and Internal Medicine, The University of Texas Health Science Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX, 75235, USA

    D. Craig Brater M.D. & Michael R. Vasko Ph.D.

  2. Veterans Administration Medical Center, 4500 Lancaster Road, Dallas, TX, 75216, USA

    D. Craig Brater M.D. & Michael R. Vasko Ph.D.

Authors
  1. D. Craig Brater M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael R. Vasko Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Basel, Switzerland

    Ernst Jucker

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Birkhäuser Verlag Basel

About this chapter

Cite this chapter

Craig Brater, D., Vasko, M.R. (1985). Update of cardiovascular drug interactions. In: Jucker, E. (eds) Progress in Drug Research. Progress in Drug Research, vol 29. Birkhäuser Basel. https://doi.org/10.1007/978-3-0348-9315-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-9315-2_1

  • Publisher Name: Birkhäuser Basel

  • Print ISBN: 978-3-0348-9992-5

  • Online ISBN: 978-3-0348-9315-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation